Evidence map›Paper›PMID 33500383›Full record

ArticleTranslational psychiatry2021

Serum D-serine levels are altered in early phases of Alzheimer's disease: towards a precocious biomarker.

Luciano Piubelli, Loredano Pollegioni, Valentina Rabattoni, Marco Mauri, Lucia Princiotta Cariddi, Maurizio Versino, Silvia Sacchi

Open access · goldAbstract read
In one paragraph

Article in Translational psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 72 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Advances in Chiral Metabolomic Profiling and Biomarker Discovery.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Luciano PiubelliDepartment of Biotechnology and Life Sciences, University of Insubria, Varese, Italy. luciano.piubelli@uninsubria.it.ORCID 0000-0003-0805-5121
Loredano PollegioniDepartment of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
Valentina RabattoniDepartment of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
Marco MauriDepartment of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
Lucia Princiotta CariddiCenter of Research in Medical Pharmacology, University of Insubria, Varese, Italy.
Maurizio VersinoNeurology Unit, Ospedale di Circolo and Fondazione Macchi, ASST Settelaghi, Varese, Italy.
Silvia SacchiDepartment of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.ORCID 0000-0002-2338-2561
University of Insubria · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

D-Serine acts as a co-agonist of N-methyl-D-aspartate receptors (NMDAR) which appear overactivated in AD, while D-aspartate is a modulatory molecule acting on NMDAR as a second agonist. The aim of this work is to clarify whether the levels of these D-amino acids in serum are deregulated in AD, with the final goal to identify novel and precocious biomarkers in AD. Serum levels of L- and D-enantiomers of serine and aspartate were determined by HPLC using a pre-column derivatization procedure and a selective enzymatic degradation. Experimental data obtained from age-matched healthy subjects (HS) and AD patients were statistically evaluated by considering age, gender, and disease progression, and compared. Minor changes were apparent in the serum L- and D-aspartate levels in AD patients compared to HS. A positive correlation for the D-serine level and age was apparent in the AD cohort. Notably, the serum D-serine level and the D-/total serine ratio significantly increased with the progression of the disease. Gender seems to have a minor effect on the levels of all analytes tested. This work proposes that the serum D-serine level and D-/total serine ratio values as novel and valuable biomarkers for the progression of AD: the latter parameter allows to discriminate CDR 2 and CDR 1 patients from healthy (CDR 0) individuals.

Indexed as

Alzheimer DiseaseAmino AcidsAspartic AcidBiomarkersHumansReceptors, N-Methyl-D-AspartateSerineAmino AcidsAspartic AcidBiomarkersReceptors, N-Methyl-D-AspartateSerine

Identifiers

PMID33500383
PMCPMC7838302
OpenAlexW3125104082

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.